Sleep Drug Daridorexant Found Safe for Severe Sleep Apnea Patients
A crossover trial finds daridorexant 50mg doesn't worsen breathing in severe OSA—and actually improves sleep quality.
Summary
Many clinicians avoid prescribing sleep medications to patients with obstructive sleep apnea, fearing they may suppress breathing and worsen the condition. A new randomized crossover trial tested daridorexant, an orexin receptor antagonist approved for insomnia, in 16 adults with severe OSA. Participants received either daridorexant 50mg or placebo for five nights each. The drug did not meaningfully increase the apnea-hypopnea index or reduce blood oxygen levels—the two key safety thresholds. Better yet, patients slept 32.5 minutes longer on average, fell asleep faster, and showed a trend toward waking up less during the night. Adverse events were mild and unrelated to breathing. This suggests daridorexant may be a viable option for OSA patients who also need help sleeping, though larger and longer studies are warranted.
Detailed Summary
For patients living with severe obstructive sleep apnea, insomnia treatment has long been off-limits. Most sedative-hypnotics carry warnings about respiratory depression, leaving clinicians with few options when OSA patients struggle to sleep. Daridorexant, a dual orexin receptor antagonist, works through a fundamentally different mechanism—blocking the wake-promoting orexin system rather than broadly depressing central nervous system activity—which raises the possibility it might not carry the same respiratory risks.
This randomized, double-blind, placebo-controlled crossover trial enrolled 16 adults with severe OSA (mean AHI of 51.2 events/hour) who did not have comorbid insomnia. Participants received daridorexant 50mg or placebo nightly for five days per period, with full polysomnography conducted after the final dose of each period.
On the primary safety endpoints, daridorexant performed well. The treatment difference in AHI was just -3.7 events/hour, well below the pre-specified threshold of +10 events/hour that would indicate a clinically meaningful worsening. Oxygen saturation during total sleep time dropped by only 0.12%, far short of the -2% threshold considered clinically significant. These results suggest the drug does not exacerbate sleep-disordered breathing.
On the efficacy side, daridorexant increased total sleep time by 32.5 minutes compared to placebo, shortened sleep onset latency by 10.3 minutes, and produced a trend toward reduced wake after sleep onset of 15.2 minutes. Adverse events were infrequent and mild across both groups.
These findings are clinically meaningful for practitioners managing patients with both OSA and sleep complaints. However, the trial was small (n=16), conducted at a single center, lasted only five days, and excluded patients with insomnia. Larger, longer trials in broader populations—including those with comorbid insomnia—are needed before firm clinical recommendations can be made.
Key Findings
- Daridorexant 50mg did not meaningfully worsen AHI (difference: -3.7 events/hr vs. +10 threshold) in severe OSA.
- Blood oxygen saturation was essentially unchanged (-0.12%), well within the safe threshold of -2%.
- Total sleep time increased by 32.5 minutes compared to placebo.
- Sleep onset latency shortened by 10.3 minutes; wake after sleep onset trended lower by 15.2 minutes.
- All adverse events were mild; none were related to respiratory function.
Methodology
Randomized, double-blind, placebo-controlled two-period crossover trial in 16 adults with severe OSA (AHI ≥30) without insomnia at a single sleep center. Participants received daridorexant 50mg or placebo nightly for 5 days per period, with polysomnography after the final dose. Pre-specified safety thresholds were AHI increase ≥10 events/hr and SpO2 decrease ≥2%.
Study Limitations
The trial was very small (n=16) and conducted at a single center, limiting generalizability. Treatment duration was only 5 days, so longer-term respiratory and sleep effects remain unknown. Patients with comorbid insomnia—arguably the most clinically relevant population—were excluded, and the summary is based on the abstract only as the full text was not available.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.